Cellestia Biotech Company
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistantcancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
Technology:
Prevention
Headquarters:
Basel
Funding Status:
Early Stage Venture
Investment Stage:
N/A
Founded Date:
2014
Number Of Exists:
N/A
Employee Number:
1-10
Industry:
Gene Therapy
Investor Type:
N/A